Joint Pain Injections Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Joint Pain Injections Market Analysis
Joint Pain Injections Market is expected to register a growth at a CAGR of 6% over the forecast period.
The COVID-19 pandemic restrictions affected the diagnosis and treatment of chronic diseases worldwide impacting the studied market. For instance, according to a research article titled "COVID-19 and Rheumatoid Arthritis" published in May 2021, older patients with rheumatoid arthritis (RA) were susceptible to COVID-19. RA patients had been affected by changes in access to care, telemedicine, drug shortages, anxiety, and social isolation, which contribute to disease flares. During the pandemic, access to therapy was constrained. 42% of patients reported canceled/postponed appointments and switched to telemedicine visits. Hence, COVID-19 had an adverse impact on the joint pain infection market.
In addition, the growing prevalence of arthritis and increasing geriatric population worldwide, and the increasing demand for knee pain injections are actively affecting the growth of the studied market.
According to World Population Prospects 2022 report, the percentage of the population aged 65 years and over in Sub-Saharan Africa is 3.0 in 2022 and projected to be 3.3 in 2030, in Northern Africa and Western Asia it is estimated to be 5.5 in 2022 and projected to be 7.0 in 2030, in Central and Southern Asia it is estimated to be 6.4 in 2022 and projected to be 8.1 in 2030, and in Europe and Northern America, 18.7 in 2022 and projected to be 22.0 in 2030. Since arthritis is more common in the geriatric population, the growth of the market segment is likely to increase as this population increases.
Furthermore, as per the Centers for Disease Control and Prevention's October 2021 update, 43% of osteoarthritis patients were 65 years of age or older in 2020. It also stated that the annual incidence of knee osteoarthritis is highest between 55 and 64 years old. More than half of individuals with symptomatic knee osteoarthritis are younger than 65. The surge in the geriatric population is expected to increase the burden of osteoarthritis and other disorders which is likely to augment the growth of the studied market over the forecast period.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. however, the high costs of the injections and reimbursement issues are likely to impede the market growth.
Joint Pain Injections Market Trends
This section covers the major market trends shaping the Joint Pain Injections Market according to our research experts:
Hyaluronic Acid Injections Segment is Expected to Witness Growth Over The Forecast Period.
Injections of hyaluronic acid are used to relieve osteoarthritis (OA)-related knee pain in patients who have already tried unsuccessful therapies such as acetaminophen and other painkillers. Hyaluronic acid injections have gained popularity as a non-surgical therapeutic option, particularly in light of clinicians' general reluctance to provide intraarticular corticosteroid injections repeatedly.
The market players are extensively focusing on developing novel products with many advantages and launching products frequently. For instance, In August 2021, Seikagaku Corporation launched HyLink, an intra-articular single-injection Visco supplement for the treatment of knee osteoarthritis in Taiwan, through TCM Biotech International Corp. The main ingredient is a cross-linked hyaluronate hydrogel using cross-linking technology. The launches are anticipated to augment the segment growth over the forecast period.
North America is Expected to Dominate the Joint Pain Injections Market Over The Forecast Period
North America is expected to dominate the market due to the high prevalence of musculoskeletal disorders, growing geriatric population, the strong presence of industry players in the region, better healthcare infrastructure, awareness among people and healthcare industry stakeholders about available technologies, and the high concentration of market players in the region.
According to the Centers for Disease Control and Prevention (CDC), chronic pain caused by arthritis affects millions of people in the United States every year. About one in four adults with arthritis, 15 million people report experiencing severe joint pain related to arthritis. A high adoption rate of advanced technologies is also the factor driving the growth of the market in this region. Additionally, major market players are making considerable investments in research activities, which will eventually boost the market in North America.
According to Population Reference Bureau, 2021 estimates, it is predicted that there are likely to be 95 million Americans aged 65 and over by 2060, contributing 23% of the total population. Also, as per the Statistics Canada, 2021 census, in Canada, there was an estimated 7,021,430 people aged 65 years or above in 2021, out of which 3,224,680 were males and 3,796,750 were female. The surge in geriatric population is likely to boost the demand for joint pain injections and thus boosts the growth of the market in the region.
Therefore, owing to the above-mentioned factors, the growth of the studied market is anticipated in the North America Region.
Joint Pain Injections Industry Overview
The global joint pain injections market is fragmented in nature due to the presence of many companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known. Some of the key market players are Anika Therapeutics, Inc., Zimmer Biomet, Bioventus LLC, Ferring B.V., sanofi-aventis LLC, Pfizer Inc., Eli Lilly and Company, Flexion Therapeutics, Inc., and Teva Pharmaceuticals among others.
Joint Pain Injections Market Leaders
-
Zimmer Biomet
-
Anika Therapeutics, Inc.
-
Bioventus LLC
-
Ferring B.V.
-
sanofi-aventis LLC
*Disclaimer: Major Players sorted in no particular order
Joint Pain Injections Market News
- In March 2022, Green Roads, a subsidiary of the Valens Company, made a USD 120,000 donation to the Arthritis Foundation in support of the organization's pain management initiative to advance the improved quality of life for those who live with chronic pain. This donation made Green Roads an official supporting sponsor of the Arthritis Foundation.
- In January 2022, AbbVie received the United States Food and Drug Administration (FDA) approval for SKYRIZI (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), which can be administered with a single injection four times a year.
Joint Pain Injections Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Prevalence of Arthritis and Increasing Geriatric Population Worldwide
- 4.2.2 Increasing Demand for Knee Pain Injections
-
4.3 Market Restraints
- 4.3.1 High Costs of the Injections
- 4.3.2 Reimbursement Issues
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 Type of Injection
- 5.1.1 Steroid Joint Injections
- 5.1.2 Hyaluronic Acid Injections
- 5.1.3 Platelet-rich Plasma (PRP) Injections
- 5.1.4 Placental Tissue Matrix (PTM) Injections
- 5.1.5 Others
-
5.2 Applications
- 5.2.1 Shoulder & Elbow
- 5.2.2 Knee & Ankle
- 5.2.3 Spinal Joints
- 5.2.4 Hip Joint
- 5.2.5 Others
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Anika Therapeutics, Inc.
- 6.1.2 Bioventus.
- 6.1.3 Ferring Pharmaceuticals Inc.
- 6.1.4 Sanofi S.A.
- 6.1.5 Pfizer Inc.
- 6.1.6 Eli Lilly and Company
- 6.1.7 Flexion Therapeutics, Inc.
- 6.1.8 Teva Pharmaceuticals
- 6.1.9 Zimmer Biomet
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityJoint Pain Injections Industry Segmentation
As per the scope of the report, joint pain injections are products that can be injected directly into the knee joint or any joints in the body to relieve pain and inflammation quickly. For patients who have inadequate responses or contraindications to systemic anti-inflammatory or analgesic drugs, joint pain injections are preferred. The Joint Pain Injections Market is segmented by Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, and Others), Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| Type of Injection | Steroid Joint Injections | |
| Hyaluronic Acid Injections | ||
| Platelet-rich Plasma (PRP) Injections | ||
| Placental Tissue Matrix (PTM) Injections | ||
| Others | ||
| Applications | Shoulder & Elbow | |
| Knee & Ankle | ||
| Spinal Joints | ||
| Hip Joint | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Joint Pain Injections Market Research FAQs
What is the current Global Joint Pain Injections Market size?
The Global Joint Pain Injections Market is projected to register a CAGR of 6% during the forecast period (2024-2029)
Who are the key players in Global Joint Pain Injections Market?
Zimmer Biomet, Anika Therapeutics, Inc., Bioventus LLC, Ferring B.V. and sanofi-aventis LLC are the major companies operating in the Global Joint Pain Injections Market.
Which is the fastest growing region in Global Joint Pain Injections Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Joint Pain Injections Market?
In 2024, the North America accounts for the largest market share in Global Joint Pain Injections Market.
What years does this Global Joint Pain Injections Market cover?
The report covers the Global Joint Pain Injections Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Joint Pain Injections Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Joint Pain Injections Industry Report
Statistics for the 2024 Joint Pain Injections market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Joint Pain Injections analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
